Genaera Corporation (NASDAQ: GENR)

Genaera Corporation (NASDAQ: GENR) has their efforts focused on advancing the science and treatment of metabolic diseases. They have identified significant market opportunities with a first-in-class molecule that may revolutionize the treatment paradigm for obesity and type 2 diabetes. They currently have two products in their pipeline: MSI-1436 , the core internal asset of Genaera designed to treat obesity and has applicability in type 2 diabetes; and MEDI-528, which is under evaluation in Phase 2 clinical studies for the treatment of asthma. For further information, visit the Company’s web site at www.genaera.com Generex is focused on researching, developing, and commercializing drug delivery systems and technologies. Their proprietary platform technology delivers drugs into the human body orally (with no deposit in the lungs). Through the utilization of the company’s liquid formulations, drugs that are typically administered by injection can be absorbed into the body through the lining of the inner mouth using the Company’s proprietary RapidMist(tm) device. For further information, visit the Company’s web site at www.generex.com.